Greg Avery writes:
The year 2014 was going to be important for Cell Point LLC anyway — but then a serendipitous discovery made it even bigger for the Centennial-based biotech research company.
Cell Point is halfway through a pivotal study of a cancer-detection agent, and it plans to apply late this year for approval to sell it in the U.S. for lung cancer treatment. Commercial use of the product, called Oncardia, may be approved in Brazil by fall for detecting a variety of cancers in patients.
To read the full story, click here: http://www.bizjournals.com/denver/print-edition/2014/01/24/cell-point-takes-heart-from-discovery.html?surround=etf&ana=e_article
